MARKET

MNOV

MNOV

MediciNova Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

4.910
+0.240
+5.14%
After Hours: 4.900 -0.01 -0.20% 19:47 09/25 EDT
OPEN
4.900
PREV CLOSE
4.670
HIGH
5.08
LOW
4.730
VOLUME
813.11K
TURNOVER
--
52 WEEK HIGH
13.25
52 WEEK LOW
2.790
MARKET CAP
219.85M
P/E (TTM)
-18.6763
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Mid-Afternoon Market Update: Dow Surges 250 Points; Owens & Minor Shares Spike Higher
Toward the end of trading Thursday, the Dow traded up 0.95% to 27,016.52 while the NASDAQ rose 1.12% to 10,751.55. The S&P also rose, gaining 0.97% to 3,268.43.
Benzinga · 2d ago
MediciNova slumps 23% on ibudilast data in chemo-induced nerve damage
MediciNova tanks ([[MNOV]] -22.3%) on average volume as investors appear underwhelmed with results from a small pilot study in Australia evaluating ibuilast (MN-166) for prevention of chemotherapy-induced peripheral neuropathy ((CIPN)).16 patients with
Seekingalpha · 2d ago
EXAS, OMI, GLNG and DGLY among midday movers
Gainers: Sunworks (SUNW) +301%.The Peck Company (PECK) +172%.Just Energy (JE) +77%.Polar Power (POLA) +74%.Owens & Minor (OMI) +56%.Net Element (NETE) +41%.Kaleido Biosciences (KLDO) +38%.LogicBio Therapeutics (LOGC) +33%.Exact Sciences (EXAS) +24%.Pioneer Power Solutions
Seekingalpha · 2d ago
Mid-Day Market Update: US Stocks Turn Higher; Kubient Shares Plunge
Midway through trading Thursday, the Dow traded up 0.45% to 26882.52 while the NASDAQ rose 1.14% to 10,754.07. The S&P also rose, gaining 0.72% to 3,260.23.
Benzinga · 2d ago
Owens & Minor, Kaleido Biosciences among major healthcare gainers, MediciNova, Rite Aid leads losers pack
Gainers: Owens & Minor (OMI) +53%, Kaleido Biosciences (KLDO) +39%, LogicBio Therapeutics (LOGC) +30%,  Cellect Biotechnology (APOP) +25%, Neuronetics (STIM) +6%.Losers: MediciNova (MNOV) -20%, Rite Aid (RAD) -17%, ADiTx Therapeutics (ADTX) -12%, NanoVibronix (NAOV) -12%, Rockwell Medical (RMTI) -10%.
Seekingalpha · 2d ago
Company News for Sep 24, 2020
Companies in the news are: JKS, JNJ, SPI, MNOV
Zacks · 2d ago
NKLA, GLNG leads the premarket losers pack
Kubient (KBNT) -21% on Q2 2020 Results Earnings call.Nikola  (NKLA) -12% after WSJ warns on stalled talks with potential partners.NanoVibronix (NAOV) -10%.Golar LNG  (GLNG) -9%.Digital Ally (DGLY) -8%.DiamondPeak Holdings (DPHC) -8%.AIM ImmunoTech  (AIM) -7%.Penn
Seekingalpha · 2d ago
MediciNova's ibudilast shows positive effect in preventing chemo-induced neuropathy
MediciNova (MNOV) has announced clinical findings published in Cancer Chemotherapy and Pharmacology, related to MN-166 (ibudilast) as a treatment for prevention of chemotherapy-induced peripheral neuropathy ((CIPN)).14 patients completed two cycles of chemotherapy, including
Seekingalpha · 2d ago
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of MNOV. Analyze the recent business situations of MediciNova Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average MNOV stock price target is 18.50 with a high estimate of 26.50 and a low estimate of 11.00.
EPS
Institutional Holdings
Institutions: 70
Institutional Holdings: 11.05M
% Owned: 24.68%
Shares Outstanding: 44.78M
TypeInstitutionsShares
Increased
19
372.39K
New
18
-122.64K
Decreased
14
331.99K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+3.04%
Pharmaceuticals & Medical Research
+1.58%
Key Executives
Chairman/Independent Director
Jeffrey Himawan
President/Chief Executive Officer/Director
Yuichi Iwaki
Chief Financial Officer
Edward Stepanow
Vice President/IR Contact Officer
Geoffrey O'Brien
Vice President/IR Contact Officer
Geoffrey O'brien
Other/Director
Kazuko Matsuda
Independent Director
Yutaka Kobayashi
Independent Director
Hideki Nagao
  • Dividends
  • Splits
  • Insider Activity
No Data
  • All
  • Financials
  • Insiders
More
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About MNOV
Medicinova, Inc. is a biopharmaceutical company. The company is focused on developing small molecule therapeutics for the treatment of serious diseases with unmet medical needs. The Company is developing activities on MN-166 (ibudilast) for neurological disorders, such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction (methamphetamine dependence, opioid dependence, and alcohol dependence), and MN-001 (tipelukast) for fibrotic diseases, such as nonalcoholic steatohepatitis (NASH) and idiopathic pulmonary fibrosis (IPF). The Company’s pipeline includes MN-221 (bedoradrine) for the treatment of acute exacerbation of asthma and MN-029 (denibulin) for solid tumor cancers.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of MediciNova, Inc. stock information, including NASDAQ:MNOV real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MNOV stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading MNOV stock methods without spending real money on the virtual paper trading platform.